Search Results
Sep 16, 2025, 07:30 ET Welsh, Carson, Anderson & Stowe Welcomes Gene Lockhart as Operating Partner
industries, today announced that Gene Lockhart, former CEO and President of Mastercard and former President of the Global Retail Bank at Bank of America has joined the firm as an operating partner. "Gene is one of the most accomplished and respected executives in
More news about: Welsh, Carson, Anderson & Stowe
Sep 16, 2025, 07:25 ET Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Solutions
Sep 16, 2025, 07:00 ET K36 Therapeutics Provides Clinical Update on KTX-1001 in Multiple Myeloma
initial data in mid-2026. KTX-1001 is designed to selectively inhibit NSD2 and reduce levels of the epigenetic mark H3K36me2, restoring balance to gene expression and re-sensitizing tumor cells to therapy. In preclinical models, KTX-1001 reduced H3K36me2 levels in t(4;14) multiple myeloma, suppressed
More news about: K36 Therapeutics
Sep 15, 2025, 11:13 ET Cancer Gene Therapy Market Size Worth US$ 19.97 Billion by 2033, with a 19.8% CAGR Growth, Report by DataM Intelligence
https://www.datamintelligence.com/download-sample/cancer-gene-therapy-market Gene Induced Immunotherapy (GII) segment is expected to dominate the market growth Gene induced immunotherapy segment is expected to hold the dominant
More news about: DataM Intelligence 4 Market Research LLP
Sep 15, 2025, 10:17 ET Pediatric Clinical Trials Market Size Worth US$ 31.77 Billion by 2033, with a 5.5% CAGR Growth, Report by DataM Intelligence
enhancing trial recruitment and data capabilities. The region is also a key hub for innovative pediatric products, including next-gen vaccines and novel gene therapies, backed by government funding and private R&D collaborations. Europe Pediatric Clinical Trials Market Poised for Significant
More news about: DataM Intelligence 4 Market Research LLP
Sep 15, 2025, 10:01 ET Made Scientific and Basilard BioTech Announce Technology Partnership to Advance Ex Vivo Gene Delivery for T Cell and iPSC Therapies
California biotechnology company pioneering novel delivery technologies for cell and gene therapy, today announced a strategic collaboration to accelerate the development and translation of Basilard BioTech's nanomechanical gene delivery platform, Celletto™.
More news about: Made Scientific, Inc.
Sep 15, 2025, 09:03 ET LabConnect and OmniScience to Deliver First Agentic AI Solution for Real-Time Clinical Trial Lab Insights
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Sep 15, 2025, 09:03 ET LabConnect and OmniScience to Deliver First Agentic AI Solution for Real-Time Clinical Trial Lab Insights
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Sep 15, 2025, 08:00 ET Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
including nausea, vomiting and muscle loss, and are difficult to adhere to over time. The INHBE gene, found in the liver, produces Activin E, a protein that helps control fat metabolism. People with certain INHBE gene changes have better fat distribution, body composition, healthier cholesterol levels, and
More news about: Rona Therapeutics
Sep 15, 2025, 08:00 ET Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
including nausea, vomiting and muscle loss, and are difficult to adhere to over time. The INHBE gene, found in the liver, produces Activin E, a protein that helps control fat metabolism. People with certain INHBE gene changes have better fat distribution, body composition, healthier cholesterol levels, and
More news about: Rona Therapeutics
Sep 15, 2025, 08:00 ET Matica Bio Secures Commercial Manufacturing Deal with U.S. Biotech Company
Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing for cell and gene therapies, today announced a strategic commercial manufacturing agreement with a clinical-stage biotech company based in the
More news about: Matica Biotechnology, Inc.
Sep 15, 2025, 07:31 ET You've never seen corn like this before
single-cell RNA sequencing, allows researchers to see how genes are expressed in thousands of cells at once. "The great thing is that you have this atlas of gene expression," Jackson says. "When we publish that, the whole community can use it. Other people interested in maize or Arabidopsis stem cells don't have
More news about: Cold Spring Harbor Laboratory
Sep 15, 2025, 07:30 ET Abzena Enhances AbZelectPRO™ Cell Line Offering with New GS Knockout Platforms
UNic® vector technology. ProteoNic collaborates with partners across the biopharmaceutical industry to bring innovative biologics as well as cell and gene therapies to market faster and more efficiently. For more information, visit proteonic.nl.
More news about: Abzena
Sep 15, 2025, 07:00 ET Deerfield Management and the Deerfield Foundation Announce Third Annual AML Summit and Recipient of American Society of Hematology (ASH) Peter Steelman Scholar Award
enhancing targeted immunotherapies and improving outcomes for patients with blood cancers. Dr. Casirati's research has contributed to the development of gene-editing approaches aimed at making bone marrow transplants and CAR-T cell therapies safer and more effective. "Congratulations to Gabriele Casirati,
More news about: Deerfield Management Company, L.P.
Sep 15, 2025, 06:00 ET Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
eradicating disease and prolonging survival.Robust expansion from both healthy donor and patient T cells, with a favorable memory phenotype and no gene editing required to avoid fratricide.The study confirms that CD84 is consistently overexpressed in AML and T-ALL, including high-risk subtypes
More news about: Gyala Therapeutics
Sep 15, 2025, 06:00 ET Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
eradicating disease and prolonging survival.Robust expansion from both healthy donor and patient T cells, with a favorable memory phenotype and no gene editing required to avoid fratricide.The study confirms that CD84 is consistently overexpressed in AML and T-ALL, including high-risk subtypes
More news about: Gyala Therapeutics
Sep 12, 2025, 10:01 ET Ligase Enzymes Market worth US$0.36 billion by 2030 with 6.8% CAGR | MarketsandMarkets™
applications continue to dominate due to their essential role in academic research, functional genomics, and biopharmaceutical development. The growth of gene therapy and the expansion of recombinant protein production pipelines further reinforce the demand for ligase enzymes in cloning. Moreover, technological
More news about: MarketsandMarkets
Sep 12, 2025, 04:43 ET Kanazawa University research: Thermal trigger
other biomolecules, additional thermogenetic tools can be developed to modulate various cellular functions, such as enzyme activity, protein–protein interactions, and gene expression." Figure 1.
More news about: Kanazawa University
Sep 12, 2025, 01:51 ET IASO Bio to Present Promising Findings on Equecabtagene Autoleucel for Multiple Sclerosis at both ANA and ECTRIMS 2025
(Eque-cel) Equecabtagene Autoleucel (Eque-cel) is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation
More news about: IASO Bio
Sep 12, 2025, 01:14 ET Performance Brokerage Services Advises on the Sale of Saskatchewan's #1 RV Dealer, Minard's Leisure World in Weyburn and Watrous to Traveland RV
Watrous, Saskatchewan from Susan and Gene Minard to Traveland RV. Minard's Leisure World, founded in 2004 by Susan and Gene Minard, is the #1 volume RV dealer in Saskatchewan.
More news about: Performance Brokerage Services, Inc.
Sep 11, 2025, 17:31 ET Dyslipidemia Market is Anticipated to Accelerate in the Coming 10 Years Due to the Development of New Classes of Drugs, Such as CETP Inhibitors and Gene-based Therapies | DelveInsight
Dyslipidemia Drug Classes Development of new classes of drugs, such as CETP inhibitors (NewAmsterdam Pharma's Obicetrapib) and gene-based therapies, holds promise for better management of dyslipidemia. Launch of Emerging Dyslipidemia Drugs The dyslipidemia
More news about: DelveInsight Business Research, LLP
Sep 11, 2025, 12:02 ET Precision Medicine Market to Reach USD 103.73 Billion by 2035, with CAGR 11.3% Driven by Genomics, AI Integration, and Targeted Therapies - Vantage Market Research
especially in oncology. The Therapeutics segment is expanding rapidly, driven by monoclonal antibodies, gene therapy, and cell therapy. Among these, monoclonal antibodies hold the largest share, while gene and cell therapies are witnessing the fastest growth with approvals for rare diseases and advanced cancers.
More news about: Vantage Market Research
Sep 11, 2025, 09:41 ET Gene Solutions Secures Patent(1) for Breakthrough Mitochondrial Therapy Platform Targeting Neurological Diseases
groundbreaking technology, collaborative opportunities, or the company's therapeutic programs, please visit the Gene Solutions website or contact the company directly. About Gene SolutionsGene Solutions is a biotechnology company specializing in therapeutic research for CNS diseases, with a
More news about: Gene Solutions
Sep 11, 2025, 08:46 ET Korea University Study Reveals Hidden Complexity in Recurrent Brain Tumors
Single-cell insights uncover the gene driving recurrence and treatment resistance in meningiomas SEOUL, South Korea, Sept. 11, 2025 /PRNewswire/
More news about: Korea University College of Medicine
Sep 11, 2025, 08:17 ET Nicholas Richardson, DO, MPH, Departs FDA and Joins Precision for Medicine as VP, Clinical Development
role, Dr. Richardson will be responsible for partnering with life science companies on the clinical development of their drugs, biologics, and cell and gene therapies.
More news about: Precision Medicine Group